Cost-effectiveness of drug therapies in benign prostatic hyperplasia in the University of Ilorin Teaching Hospital, Nigeria
Journal of Pharmaceutical Sciences and Pharmacy Practice · 2024 · 13 (1&2) · 9-15
DOI: 10.52968/15608473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences and Pharmacy Practice, 2024. Verfasst von H.B. Giwa und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Background
A growing global population and an aging demographic necessitate enhanced strategies for the prevention and management of Benign Prostatic Hyperplasia (BPH), given its projected rise in prevalence. Methodology: A sample size of 405 patients, along with their corresponding case notes, was selected from the total population of patients diagnosed with benign prostatic hyperplasia (BPH). A drug utilization study was conducted through a one-year retrospective review (January 2022 to December 2022) of the case notes. The EuroQol 5-Dimensions 5-Level questionnaire (EQ-5D-5L) was used to determine the effectiveness of treatment options based on quality-adjusted life years (QALYs). Cost-effectiveness was expressed as cost per QALY, measured against World Health Organization (WHO) cost- effectiveness thresholds.
Results
Two hundred and ten of the selected cases were placed on Tamsulosin monotherapy (51.9%), 165 (40.7%) on Tamsulosin + Dutasteride, 15 (3.7%) on Tamsulosin + Silodosin, and 15 (3.7%) on Tamsulosin + Finasteride. The average cost and effectiveness (QALY) were as follows: Tamsulosin – $52.6 (4.2597); Tamsulosin + Dutasteride – $249.42 (4.3182); Tamsulosin + Silodosin – $370.43 (3.6684); and Tamsulosin + Finasteride – $518.61 (4.3640). There was a statistically significant difference in the effectiveness of the treatment options. When compared with Tamsulosin, the following Incremental Cost-Effectiveness Ratios (ICERs) were observed: $3363.59/QALY for Tamsulosin + Dutasteride, $3046.79/QALY for Tamsulosin + Finasteride, and Tamsulosin + Silodosin was less cost-effective (dominated). These ICERs were robust under sensitivity analysis.
Conclusions
In the Nigerian healthcare system, Tamsulosin + Dutasteride and Tamsulosin + Finasteride were more cost-effective than the other identified treatment options.
Zitieren
APA
Giwa, H., Ajulo, A., Aiyelero, O., Giwa, A., Jamiu, O., Shittu, A., Njinga, S., & Abduli, A. (2024). Cost-effectiveness of drug therapies in benign prostatic hyperplasia in the University of Ilorin Teaching Hospital, Nigeria. Journal of Pharmaceutical Sciences and Pharmacy Practice, 13(1&2), 9-15. https://doi.org/10.52968/15608473
Vancouver
Giwa H, Ajulo A, Aiyelero O, Giwa A, Jamiu O, Shittu A, et al. Cost-effectiveness of drug therapies in benign prostatic hyperplasia in the University of Ilorin Teaching Hospital, Nigeria. Journal of Pharmaceutical Sciences and Pharmacy Practice. 2024;13(1&2):9-15. doi:10.52968/15608473
BibTeX
@article{Giwa2024,
author = {Giwa, H.B. and Ajulo, A.A. and Aiyelero, O.M. and Giwa, A. and Jamiu, O.M. and Shittu, A.O. and Njinga, S. and Abduli, A.},
title = {Cost-effectiveness of drug therapies in benign prostatic hyperplasia in the University of Ilorin Teaching Hospital, Nigeria},
journal = {Journal of Pharmaceutical Sciences and Pharmacy Practice},
year = {2024},
volume = {13},
number = {1&2},
pages = {9--15},
doi = {10.52968/15608473}
}
EUVIMED